A Multiple Ascending Dose Study of COR388

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions

Alzheimer Disease

Interventions

DRUG

COR388

COR388 administered for 10 or 28 days.

DRUG

Placebo

Placebo administered for 10 or 28 days.

Trial Locations (3)

Bioclinica Research, Orlando

Medpace Clinical Pharmacology Unit, Cincinnati

Pacific Research Network, San Diego